On November 5, 7th China International Import Expo (hereinafter referred to as "Expo") officially opened, bring and many innovative drugs in the field of kidney therapy for the seventh consecutive year.
Among them, Innovative drug combinations for IgA nephropathy (iAgan) Avson Tan and Fechida ® (Ipko Capylin Hydrochloride Capsule) The first joint appearance showed Novartis in the field of kidney therapyNew layout.
Avson Tan, an endothelin A receptor antagonist, which is the first domestic non -immune to be listed on the marketClass, high -selective Igan precision therapeutic drugs.
Ipco Capylin Hydrochloride It is currently the worlds first primitive approval to reduce the risk of rapid progress.Iga nephropathy (Igan) proteinuriacipation of the body bypass pathway inhibitors, is also expected to accelerate the expansion of Igan and other kidney field indications in China that has been approved in China to accelerate the expansion.It brings more targeted treatment plans to Chinese iGAN patients, and starts a new era of precision treatment.
Novartis 2024 Expo booth
Yao said: "Novartis is the full diligence participating in the seventh -session of the Expo. In the past six years, thanks to the platform effect and overflowing effects in the Expo, NovartisThe speed has been continuously improved, and a variety of products have successfully moved from the Expo to the big market in China.The new renal product portfolio of the first show is expected to provide more accurate and safe solutions for domestic kidney disease treatment.In the future, Novartis will continue to focus on the needs of domestic patients in core treatment fields such as cardiovascular, kidney and metabolism, and develop and introduce more innovative drugs to fill the gap in clinical treatment and protect patients heart and kidney health."35HK0LQP"> Continue to consolidate the field of cardiovascular disease, so that innovative drugs are more andCardiovascular disease is the "first account number that leads to the death of Chinese residents.Killer " [1] , is also one of the key areas of the disease focusing on Novartis. According to calculations, the number of patients with cardiovascular disease in China is as high as 330 million, and the prevalence is still in the rise.At the same time, 2 of each of the deaths in my country died of cardiovascular disease.Behind these numbers are living and happy families.
Over the years, Novartis has paid in -depth attention to the needs of patients with cardiovascular diseases in China.Tastein receptorcerin enzyme inhibitors (ARNI) Pharmaceutical Norkedo® (sodium sodium soda tablets of Sakubabebutan), the worlds first small interference RNA cholesterol reduction drugs ®), Bring the gospel for patients with heart failure, hypertension, and hyperlipidemia.With the opening platform of the Expo, "Baby of the Board" Yingke Silan successfully moved from "First Show Show" to clinical application in 2023, providing a convenient blood lipid management solution for doctors and patients.
Novartis will also actively respond to the call of "Healthy China" this year, further promote the accessibility of Yingke Silan, and meet the unfinished needs of patients with cardiovascular disease.
Novartis, kidney and metabolism (CRM)
Key products in the core therapyIn addition to providing an innovative treatment plan, Novartis also deeply insists on the current status of the publics lack of awareness of cardiovascular disease.In order to promote common cardiovascular disease such as hypertension and abnormal blood lipids, help the publics health literacy improvement, and promote the prevention and treatment of cardiovascular diseases further forward.
Add the field of kidney disease to make clinical treatment more accurate
Cardiovascular disease and kidney diseaseThe relationship is close.
A new type of disease concept proposed by the American AHA "Chairmans Proposal" in 2023, that is, "Heart-kidney-metabolism syndrome", published in "Cycling" magazineIt was rated as "9 major progress in the field of cardiovascular disease prevention and control in 2023", which once again revealed the close connection between cardiovascular disease and chronic kidney disease, and often merged, which greatly increased the difficulty of disease management.
During the Expo this year, Novartis brought an innovative drug group Avoson Tan and Ipko Capsules for Igans treatmentThe determination and actions of the increase in the field to benefit more Igan patients.
Igan is a highly heterogeneous autoimmune disease. The immune system attacks the kidneys and causes glomerular inflammation and proteinuria [2].The characteristics of fast progress. Igan is the most common primary glomerular disease in China, with a number of patients about 4 million [3] .
The disease is high in the young people, and the progress is hidden and fast, which seriously threatens the quality of life and life of patients in the golden age of life.Even the society has a serious burden. Lgan is far faster than we can imagine.According to the retrospective queue of the British Registration Office, even if the urine protein is controlled at 0.44 ~ 0.88 g/d, the risk of renal failure within 10 years is still 30%[4].
At present, the four -weight strike theory of the IgAN pathogenesis in the world, that is, a variety of pathological mechanisms participate in their onset, leading to kidney damage.This doctrine also guides the research of Igan precision drugs. Patients can bring significant proteinuria and renal protection through precision treatment, delay the progress of the disease and delay the time of patients entering the kidney failure.
Avson Tan, which appeared at the Expo this Expo, is the first domestic non -immunization, high -selective Igan to be listed on the market.Precision therapeutic drugs are acting in endothelin A receptor. Abu Shengtan can reduce the internal pressure of the glomerular balls, reduce kidney burden, inflammation, foot cell damage and proteinuria, delay film cell proliferation and fibrosis.
Ipko Capsule Capsule, which is unveiled at the same time, is a oral, selective B factor inhibitor, and the worlds first approved targeted complement bodyIgan therapy of bypass. The excessive activation of the body in the kidney is considered one of the pathogenesis of Igan [4].The targeted inhibitory effect of Ipke Capyl Hydrochloride Capsules can effectively reduce kidney damage and play a clear and accurate treatment role.
Feheda ®Region, in Asia, especially domestic IgA nephropathy is high. Due to factors such as the characteristics of the disease and the treatment concept of patients, East Asian patients have a higher incidence and the prognosis is worse.It is easy to advance to uremia or even renal failure.ID = "35HK0LSH"> Professor , chief physician of the Department of Nephrology, the Department of Nephrology, Affiliated to the School of Medicine of Shanghai Jiaotong University pointed out that "currently there are still nearly half of the continuous protein urine Igan patients in the current standard treatment plan.After the diagnosis, it has progressed within 10 to 20 years of renal failure, facing the situation of maintaining sexual dialysis and/or kidney transplantation.At the same time, the precise treatment plan is started, grasped with both hands, grasping the best treatment time, and fully helping patients to reduce and reverse proteinuria, delay the progress of the disease. Entering dialysis at the age of 50 and 80 years of dialysis will be a completely different life. "
Ipke Capyl Hydrochloride Capsule was approved by the US FDA in August 2024 to reduce the proteinuria of adult Igan patients with rapid progress risks. Application for adaptive expansion in the field of kidney disease in China has also been accepted by the China State Drug Administration. It is expected to make Chinese patients and global patients synchronize to the most cutting -edge innovative treatment.
As an important part of the product pipeline in the field of Nuohuas kidney disease, ovistein, Ipko Capsules, and another Novartis research product Zigakibart,It will cover six major indications to rewrite the current status of diagnosis and treatment of Chinese iAgan and other kidney diseases in the form of "combination boxing".
· The purpose of this information is to convey the cutting -edge information and research progress of pharmaceuticals, non -advertising purposes.The information involved in this information is for reference only. Please follow the opinions or guidance of doctors or other medical and health professionals.
· The adaptive symptoms of the adaptive disease in the adaptive symptoms of Avan Tanfan ® ®
